AMGEN INC (AMGN)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$429.88
-0.59%
Investru Score
55.0 / 100
Good
Why is AMGN moving?
AMGN is down 0.59% today, a pullback within its broader uptrend.
Business overview
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Bull case
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Bear case
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
Want the complete AI research memo? Unlock full stock analysis →
Score breakdown
- Financial Quality
- 71
- Growth
- 45
- Profitability
- 51
- Balance Sheet
- 15
- Valuation
- 65
- Momentum
- 87
Financial quality
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
- ROIC
- 13.1%
- ROE
- 89.1%
- FCF Margin
- 22.0%
- Free Cash Flow (TTM)
- $8.1B
- Earnings Quality (OCF ÷ Net Income)
- 1.3x
Valuation
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
- P/E (TTM)
- 26.2x
- Forward P/E
- Data unavailable
- PEG (P/E ÷ EPS Growth)
- 0.3x
- Company Median PEG
- 0.3x
- Price / Sales
- 6.2x
- EV / EBITDA
- 22.2x
- FCF Yield
- 3.5%
Key risks
- AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.(Probability: Medium · Impact: Medium)
Latest earnings
- Q2 FY26 EPS
- $4.37
- Estimate
- Data unavailable
- Surprise
- Data unavailable
AI explanation unavailable — the numeric report above is real; only this narrative text couldn't be generated right now.
SEC filings
- 10-Q · Q2 FY26 · period ended 2026-06-30Filed 2026-08-05
- 10-Q · Q1 FY26 · period ended 2026-03-31Filed 2026-05-01
- 10-K · FY25 · period ended 2025-12-31Filed 2026-02-13
- 10-Q · Q3 FY25 · period ended 2025-09-30Filed 2025-11-05
- 10-Q · Q2 FY25 · period ended 2025-06-30Filed 2025-08-06
- 10-K · FY24 · period ended 2024-12-31Filed 2025-02-14
- 10-K · FY23 · period ended 2023-12-31Filed 2024-02-14
- 10-K · FY22 · period ended 2022-12-31Filed 2023-02-09
- 10-K · FY21 · period ended 2021-12-31Filed 2022-02-16
Event filings (8-K) aren't covered by this page's data source yet — only 10-K/10-Q are shown above.
Market cap $231.6B · 52-week range $269.77–$447.03 · market data as of Aug 31, 2026, 4:00 PM ET · latest SEC filing: 2021-08-04
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze AMGN with Investru AINot investment advice. Investru AI summarizes public data and AI-generated analysis for informational purposes only.